Dr. Richard Scranton
Dr. Richard Scranton completed his Internship and Residency in Internal Medicine at the Naval Medical Center in Portsmouth, Virginia in 1997 and served as the Chief Resident for the 1998 academic year. From 1998 through 2000, Dr. Scranton was an Assistant Clinical Professor of Medicine at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences. He completed his Harvard General Medicine Fellowship and received an MPH from the Harvard School of Public Health in 2002. He served as Associate Physician in the Division of Aging at Brigham and Women’s Hospital and Associate Physician in General Internal Medicine, Beth Israel Deaconess Hospital, Boston, MA and, Assistant Professor, Harvard medical school. As a clinician investigator, his research focus includes clinical trials, health services research, and epidemiology. As Principal Investigator of multicenter US and international trials, Dr. Scranton has coordinated all aspects of the research activity including FDA regulatory filing. He has conducted and designed numerous epidemiologic and economic database studies. His efforts as Chief Medical Officer of VeroScience led to the successful FDA approval of a first-in-class centrally acting drug indicated for the treatment of type 2 diabetes. Currently he serves as the Executive Medical Director of Medical Health Sciences for Pacira Pharmaceuticals where he directs a field-based Scientific Affairs and Medical Education team as well as manages phase IV studies that relate to health outcomes and patient-reported outcomes.